Weight Loss, Danish drugmaker

US FDA says shortage of Novo's weight-loss drug resolved
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday.
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
New weight loss drugs aim to promote muscle growth
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate
Is Ozempic safe for weight loss? What doctors want you to know about blockbuster drug
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 drugs, and whether they're safe.
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, it has also come with its share of notable side effects.
Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line ...
The Motley Fool19d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.
pharmaphorum4d
Novo Nordisk says oral Wegovy hits weight loss goal
Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug Wegovy hit the mark ...
The next phase of the weight-loss revolution holds promise — and peril
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Are Weight Loss Injections Safe? What to Know Before Starting One
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...